Literature DB >> 8096351

The interferon-induced double-stranded RNA-activated human p68 protein kinase inhibits the replication of vaccinia virus.

S B Lee1, M Esteban.   

Abstract

The interferon-induced, double-stranded RNA (dsRNA)-activated protein kinase (p68 kinase) has long been implicated as one of the antiviral agents responsible for overcoming virus infections. To investigate the antiviral potential of p68 kinase, we have generated a recombinant vaccinia virus that expresses human p68 kinase under the control of lac operator/repressor element. Upon induction of p68 kinase gene with the inducer isopropyl-beta-D-thiogalactoside (IPTG), we observed in cultured cells a severe (> 90%) inhibition of virus protein synthesis; this inhibition correlated with autophosphorylation of p68 kinase. As a result of inhibition in the synthesis of virus polypeptides, there was a 100-fold decrease in virus yields. When cells were infected with the recombinant virus expressing lys296-->arg296 mutant p68 kinase there was no reduction in virus yields. Our findings demonstrate that human p68 kinase once activated severely inhibits vaccinia virus replication as a result of inhibition of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096351     DOI: 10.1006/viro.1993.1223

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Cooperative roles of fish protein kinase containing Z-DNA binding domains and double-stranded RNA-dependent protein kinase in interferon-mediated antiviral response.

Authors:  Ting-Kai Liu; Yi-Bing Zhang; Ying Liu; Fan Sun; Jian-Fang Gui
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Making (anti)sense of non-coding sequence conservation.

Authors:  D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

3.  Virus infection rapidly activates the P58(IPK) pathway, delaying peak kinase activation to enhance viral replication.

Authors:  Alan G Goodman; Bertrand C W Tanner; Stewart T Chang; Mariano Esteban; Michael G Katze
Journal:  Virology       Date:  2011-05-25       Impact factor: 3.616

4.  Host-range restriction of vaccinia virus E3L-specific deletion mutants.

Authors:  E Beattie; E B Kauffman; H Martinez; M E Perkus; B L Jacobs; E Paoletti; J Tartaglia
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

Review 5.  New developments in the induction and antiviral effectors of type I interferon.

Authors:  Su-Yang Liu; David Jesse Sanchez; Genhong Cheng
Journal:  Curr Opin Immunol       Date:  2010-11-29       Impact factor: 7.486

6.  Activation of the double-stranded RNA (dsRNA)-activated human protein kinase in vivo in the absence of its dsRNA binding domain.

Authors:  S B Lee; S R Green; M B Mathews; M Esteban
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

Review 7.  Regulation of eukaryotic protein synthesis by protein kinases that phosphorylate initiation factor eIF-2.

Authors:  M J Clemens
Journal:  Mol Biol Rep       Date:  1994-05       Impact factor: 2.316

8.  Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta.

Authors:  Khaldun Al-Khatib; Bryan R G Williams; Robert H Silverman; William Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR.

Authors:  D C Thomis; C E Samuel
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling.

Authors:  S Balachandran; C N Kim; W C Yeh; T W Mak; K Bhalla; G N Barber
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.